Mastering the Art of Developing a Successful Bispecific Antibody
About this webinar
Webinar Preview
Transitioning from single-functional antibodies to sophisticated bispecific designs introduces unique challenges. Unlike traditional antibodies, bispecifics require tailored screening strategies to identify the most effective format.
Join us to gain valuable insights into the strategies and methodologies that can help you navigate the complexities of bispecific antibody development.
In this webinar, we will explore the principles and practices of developing successful bispecific antibodies. We will delve into intelligent bispecific design, focusing on key factors such as avidity, spacing and the formatting of fragment antigen binding (Fab) and single-chain fragment vehicle (scFv) arms. Our approach aims to streamline the screening process, allowing for broad exploration with minimal designs.
Who should attend
- Biopharma CMC
- Biopharma method development
- Biopharma process development
- Biophysical Scientists in government and academia
What you will learn
- Design Considerations for Bispecific Candidates: Learn what elements to include and avoid to optimize your designs
- Improving Purity with Single-Step Purification: Discover methods to enhance antibody purity efficiently
- Case Study on Screening Strategies: Understand the importance of screening multiple designs through a detailed case study
Featured Speakers
Timothy Wood, PhD
Dr. Timothy Wood is an accomplished scientist with a robust background in technology development, honed through a PhD from the University of Edinburgh and postdoctoral research at prestigious institutions, including Brown University and the University of Cambridge.
With five years of experience in the biotech sector focused on Affimer-based therapeutics, Tim has been contributing his expertise at Abzena for over two years. As a Senior Scientist in the Protein Engineering department, he has led diverse projects in de-immunization, affinity maturation and the design and production of bispecific antibodies, demonstrating a broad and impactful skill set in the field.
Partner for this event
Abzena
Abzena is as committed to success as you are. We have the capabilities, capacity and knowledge to move your asset forward as carefully and quickly as possible.
Our seasoned professionals offer the kind of personalized service and flexible working relationship that your demanding, time-sensitive programs deserve. We’re not afraid to question assumptions, and not shy about presenting new and better ideas.
And then, we deliver.
With research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK, Abzena is fully prepared to move your bioconjugate and biologics programs forward at every step in the process.
Related webinars
More from Abzena.
Assessment of Fc-mediated Functional Activity for the Development of Complex Biologics and Bioconjugates
Accelerating Early Phase Biologics from the Clinic to Commercialization
Antibody-Drug Conjugates: Next-Generation Linker Technology for IND Submissions
Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program
Process Development: Getting from Phase I to III
Addressing Immunogenicity Challenges to Select the Best Drug Development Candidate
Oligonucleotide ADC Design and Development – An Emerging Field Building on the Success of ADCs in Cancer
Elements for Smooth Technology Transfers of Biologics Manufacturing Processes
